Home › Trials › NCT04574089
Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 55 Women only

Treatment for aerobic vaginitis using Baofukang vaginal suppository

Official title: Medical Ethics Committee of Peking University Shenzhen Hospital

Run by Peking University Shenzhen Hospital · NCT04574089 · Data updated 2026-11-12

This study tests if a new vaginal suppository can help women with aerobic vaginitis feel better, comparing two different treatment lengths of 7 days and 14 days.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 55 Years
SexWomen only
Enrollment50 (estimated)
SponsorPeking University Shenzhen Hospital
Academic / other
Locations1 site (Shenzhen, Guangdong)
StatusRecruiting
StartedMay 1, 2020
Main results expectedDecember 30, 2026
Study endsDecember 30, 2026
Registry record updatedJune 12, 2025
Trial IDNCT04574089 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are women diagnosed with aerobic vaginitis who meet specific inclusion criteria.

Probably not a fit

Patients with other types of vaginitis, serious underlying health conditions, or those who are pregnant or lactating may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of Baofukang vaginal suppository in treating aerobic vaginitis. Participants are divided into two groups, receiving either a 7-day or a 14-day course of treatment. The effectiveness of the treatment will be assessed 7 to 14 days and 35 to 42 days after the completion of the regimen. The study aims to provide insights into the optimal duration of treatment for this condition.

Why it matters

Potential benefit: If successful, this treatment could provide an effective solution for women suffering from aerobic vaginitis.

How similar studies have gone: While this approach is being evaluated in this trial, similar studies have shown promise in treating vaginitis with localized therapies.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Aerobic vaginitis diagnosed based on present ：

1. Vaginal dischareg ;
2. pH \> 4.5;
3. Donders score≥3;

Exclusion Criteria:

1. Patients with other vaginitis, cervical erosion, or suspected gonorrhea, herpes simplex virus infection and other vulvar diseases;
2. Patients received systemic or vaginal antifungal or antibiotic treatment within two weeks before admission.
3. Pregnancy, lactation and intentional pregnancy;
4. Women with liver and kidney dysfunction, low immune function, diabetes, psychosis or other serious diseases;
5. Allergic constitution and patients allergic to drug ingredients in this study;
6. Those with poor compliance.

Where it's running

  • Peking University Shenzhen Hosptal
    Shenzhen, Guangdong, China     Recruiting

Study contacts

  • Principal investigator: Shangrong Fan, M.D. — Dept of Obstetrics and Gynecology,Peking University Shenzhen Hospital
  • Study coordinator: Ping Liu, M.D.
  • Email: 253783006@qq.com
  • Phone: 86755-83923333

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Vaginitis 4Peking University Shenzhen Hospital 8
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.